262 related articles for article (PubMed ID: 34124495)
1. Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders.
Hecking J; Davoudian PA; Wilkinson ST
Chronic Stress (Thousand Oaks); 2021; 5():24705470211020446. PubMed ID: 34124495
[TBL] [Abstract][Full Text] [Related]
2. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
Wilkinson ST; Sanacora G
Drug Discov Today; 2019 Feb; 24(2):606-615. PubMed ID: 30447328
[TBL] [Abstract][Full Text] [Related]
3. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID; Park LT; Zarate CA
CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
[TBL] [Abstract][Full Text] [Related]
4. Keeping up with the clinical advances: depression.
Ragguett RM; Tamura JK; McIntyre RS
CNS Spectr; 2019 Aug; 24(S1):25-37. PubMed ID: 31248466
[TBL] [Abstract][Full Text] [Related]
5. Novel antidepressant drugs: Beyond monoamine targets.
Gonda X; Dome P; Neill JC; Tarazi FI
CNS Spectr; 2023 Feb; 28(1):6-15. PubMed ID: 34588093
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.
Vecera CM; C Courtes A; Jones G; Soares JC; Machado-Vieira R
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004437
[TBL] [Abstract][Full Text] [Related]
7. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Dean RL; Hurducas C; Hawton K; Spyridi S; Cowen PJ; Hollingsworth S; Marquardt T; Barnes A; Smith R; McShane R; Turner EH; Cipriani A
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD011612. PubMed ID: 34510411
[TBL] [Abstract][Full Text] [Related]
8. Novel glutamatergic drugs for the treatment of mood disorders.
Lapidus KA; Soleimani L; Murrough JW
Neuropsychiatr Dis Treat; 2013; 9():1101-12. PubMed ID: 23976856
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the activity of
Vasilescu AN; Schweinfurth N; Borgwardt S; Gass P; Lang UE; Inta D; Eckart S
Neuropsychiatr Dis Treat; 2017; 13():973-980. PubMed ID: 28408831
[TBL] [Abstract][Full Text] [Related]
10. [Ketamine, psilocybin, and rapid acting antidepressant: new promise for psychiatry?].
Bottemanne H; Claret A; Fossati P
Encephale; 2021 Apr; 47(2):171-178. PubMed ID: 33190819
[TBL] [Abstract][Full Text] [Related]
11. Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.
Vasiliu O
Front Pharmacol; 2022; 13():884155. PubMed ID: 35847011
[TBL] [Abstract][Full Text] [Related]
12. A hypothesis of monoamine (5-HT) - Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery.
Li YF
Pharmacol Ther; 2020 Apr; 208():107494. PubMed ID: 31991195
[TBL] [Abstract][Full Text] [Related]
13. Zuranolone and its role in treating major depressive disorder: a narrative review.
Ali M; Ullah I; Diwan MN; Aamir A; Awan HA; Waris Durrani A; Qudrat QU; Shoib S; De Berardis D
Horm Mol Biol Clin Investig; 2023 Jun; 44(2):229-236. PubMed ID: 36848317
[TBL] [Abstract][Full Text] [Related]
14. Zuranolone - synthetic neurosteroid in treatment of mental disorders: narrative review.
Marecki R; Kałuska J; Kolanek A; Hakało D; Waszkiewicz N
Front Psychiatry; 2023; 14():1298359. PubMed ID: 38116383
[TBL] [Abstract][Full Text] [Related]
15. Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders.
Costi S; Van Dam NT; Murrough JW
Curr Behav Neurosci Rep; 2015 Dec; 2(4):216-225. PubMed ID: 26783510
[TBL] [Abstract][Full Text] [Related]
16. Novel Glutamatergic Treatments for Severe Mood Disorders.
Park M; Niciu MJ; Zarate CA
Curr Behav Neurosci Rep; 2015 Dec; 2(4):198-208. PubMed ID: 26824031
[TBL] [Abstract][Full Text] [Related]
17. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
d'Andrea G; Pettorruso M; Lorenzo GD; Mancusi G; McIntyre RS; Martinotti G
Eur Neuropsychopharmacol; 2023 May; 70():49-55. PubMed ID: 36867895
[TBL] [Abstract][Full Text] [Related]
18. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
Sanacora G; Treccani G; Popoli M
Neuropharmacology; 2012 Jan; 62(1):63-77. PubMed ID: 21827775
[TBL] [Abstract][Full Text] [Related]
19. Novel drugs and therapeutic targets for severe mood disorders.
Mathew SJ; Manji HK; Charney DS
Neuropsychopharmacology; 2008 Aug; 33(9):2080-92. PubMed ID: 18172433
[TBL] [Abstract][Full Text] [Related]
20. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
McIntyre RS; Rosenblat JD; Nemeroff CB; Sanacora G; Murrough JW; Berk M; Brietzke E; Dodd S; Gorwood P; Ho R; Iosifescu DV; Lopez Jaramillo C; Kasper S; Kratiuk K; Lee JG; Lee Y; Lui LMW; Mansur RB; Papakostas GI; Subramaniapillai M; Thase M; Vieta E; Young AH; Zarate CA; Stahl S
Am J Psychiatry; 2021 May; 178(5):383-399. PubMed ID: 33726522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
